|
US3024257A
(en)
|
1961-04-10 |
1962-03-06 |
Frosst & Co Charles E |
Stable preparations of alkali metal salts of estrone sulfate
|
|
FR2340735A1
(fr)
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
|
IE52670B1
(en)
|
1981-03-03 |
1988-01-20 |
Leo Ab |
Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
|
|
DE3437232A1
(de)
|
1984-10-10 |
1986-04-17 |
Mack Chem Pharm |
Stabilisierte injektionsloesungen von piroxicam
|
|
US4782155A
(en)
|
1986-03-19 |
1988-11-01 |
Banyu Pharmaceutical Co., Ltd. |
Cephalosporin derivatives, processes for their preparation and antibacterial agents
|
|
US5139878A
(en)
|
1991-08-12 |
1992-08-18 |
Allied-Signal Inc. |
Multilayer film constructions
|
|
US5540934A
(en)
|
1994-06-22 |
1996-07-30 |
Touitou; Elka |
Compositions for applying active substances to or through the skin
|
|
US5912349A
(en)
|
1997-01-31 |
1999-06-15 |
Pharmacia & Upjohn Company |
Process for the preparation of roquinimex
|
|
US20030124187A1
(en)
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
|
US6696407B1
(en)
|
1997-03-21 |
2004-02-24 |
The Regents Of The University Of California |
Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
|
|
GB9726339D0
(en)
|
1997-12-13 |
1998-02-11 |
Zeneca Ltd |
Human-derived tissue-specific potassium channel
|
|
US6077851A
(en)
*
|
1998-04-27 |
2000-06-20 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9801474D0
(sv)
*
|
1998-04-27 |
1998-04-27 |
Active Biotech Ab |
Quinoline Derivatives
|
|
US6121287A
(en)
|
1998-07-15 |
2000-09-19 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802550D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6133285A
(en)
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802549D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
PL199781B1
(pl)
|
1999-10-25 |
2008-10-31 |
Active Biotech Ab |
Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
|
|
US6852323B2
(en)
|
2000-07-21 |
2005-02-08 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
|
US6307050B1
(en)
|
2000-08-29 |
2001-10-23 |
R. T. Alamo Venture I Llc |
Method of synthesizing flosequinan from 4-fluoroanthranilic acid
|
|
US6802422B2
(en)
|
2000-12-12 |
2004-10-12 |
Multi-Comp, Inc. |
Sealed blister assembly
|
|
US6706733B2
(en)
|
2001-05-08 |
2004-03-16 |
Dainippon Ink And Chemicals, Inc. |
Quinolinone derivative formulation and its production method
|
|
US20030119826A1
(en)
|
2001-09-24 |
2003-06-26 |
Pharmacia Corporation |
Neuroprotective treatment methods using selective iNOS inhibitors
|
|
US6875869B2
(en)
|
2002-06-12 |
2005-04-05 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
US7560557B2
(en)
|
2002-06-12 |
2009-07-14 |
Active Biotech Ag |
Process for the manufacture of quinoline derivatives
|
|
SE0201778D0
(sv)
|
2002-06-12 |
2002-06-12 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
WO2004000814A1
(en)
*
|
2002-06-25 |
2003-12-31 |
Merck Frosst Canada & Co. |
8-(biaryl) quinoline pde4 inhibitors
|
|
US7820145B2
(en)
|
2003-08-04 |
2010-10-26 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US20070292461A1
(en)
|
2003-08-04 |
2007-12-20 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
US20050074451A1
(en)
|
2003-06-25 |
2005-04-07 |
Elan Pharmaceuticals, Inc. |
Methods and compositions for treating rheumatoid arthritis
|
|
US8795693B2
(en)
|
2003-08-04 |
2014-08-05 |
Foamix Ltd. |
Compositions with modulating agents
|
|
US8314124B2
(en)
|
2004-02-06 |
2012-11-20 |
Active Biotech Ab |
Crystalline salts of quinoline compounds and methods for preparing them
|
|
SE0400235D0
(sv)
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
|
AU2005231467A1
(en)
|
2004-04-01 |
2005-10-20 |
Elan Pharmaceuticals, Inc. |
Steroid sparing agents and methods of using same
|
|
CA2579038A1
(en)
|
2004-09-02 |
2006-03-16 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
HRP20160455T1
(hr)
|
2004-09-09 |
2016-07-15 |
Yeda Research And Development Co., Ltd. |
Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
|
|
US20060205822A1
(en)
|
2004-12-22 |
2006-09-14 |
Forest Laboratories, Inc. |
1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
|
|
AU2006204699B2
(en)
|
2005-01-13 |
2012-04-26 |
Sirtris Pharmaceuticals, Inc. |
Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
|
|
CA2613678A1
(en)
|
2005-06-02 |
2006-12-07 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
KR20080074120A
(ko)
|
2005-10-13 |
2008-08-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
|
BRPI0617477A2
(pt)
|
2005-10-19 |
2011-07-26 |
Teva Pharma |
mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
|
|
AU2006307939B2
(en)
|
2005-10-26 |
2012-03-29 |
Merck Serono Sa |
Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
|
|
US20080108641A1
(en)
|
2006-02-08 |
2008-05-08 |
Ajami Alfred M |
Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
|
|
US8367629B2
(en)
|
2006-02-14 |
2013-02-05 |
Noxxon Pharma Ag |
MCP-1 binding nucleic acids and use thereof
|
|
HUE047230T2
(hu)
|
2006-02-28 |
2020-04-28 |
Biogen Ma Inc |
Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
|
|
US8410115B2
(en)
*
|
2006-02-28 |
2013-04-02 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
|
|
KR20080104343A
(ko)
|
2006-03-03 |
2008-12-02 |
엘란 파마슈티칼스, 인크. |
나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
|
|
US20070218062A1
(en)
|
2006-03-16 |
2007-09-20 |
Genentech, Inc. |
Methods of treating lupus using CD4 antibodies
|
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
WO2007146331A1
(en)
|
2006-06-12 |
2007-12-21 |
Teva Pharmaceutical Industries, Ltd. |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
CN101466379B
(zh)
|
2006-06-12 |
2012-10-31 |
泰华制药工业有限公司 |
稳定的拉喹莫德的制剂
|
|
JP2009543823A
(ja)
|
2006-07-17 |
2009-12-10 |
ノバルティス アクチエンゲゼルシャフト |
免疫調節剤として使用するための胆汁酸アミドのスルホニルアミノカルボニル誘導体
|
|
EP1886996A1
(en)
|
2006-08-10 |
2008-02-13 |
Ferrer Internacional, S.A. |
1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
|
|
ATE510538T1
(de)
|
2006-08-11 |
2011-06-15 |
Univ Johns Hopkins |
Zusammensetzungen und verfahren für nervenschutz
|
|
BRPI0715950A2
(pt)
|
2006-08-17 |
2013-07-30 |
Univ Chicago |
tratamento de doenÇas inflamatàrias
|
|
US20100136125A1
(en)
|
2006-12-28 |
2010-06-03 |
Jacobus Pharmaceutical Company, Inc. |
Method of treating inflammatory bowel disease
|
|
CA2693697C
(en)
|
2007-07-11 |
2017-07-25 |
Medicinova, Inc. |
Treatment of progressive neurodegenerative disease with ibudilast
|
|
US20100260716A1
(en)
|
2007-10-23 |
2010-10-14 |
Ucb Pharma Gmbh |
Compounds for treating demyelination conditions
|
|
WO2009082471A1
(en)
|
2007-12-20 |
2009-07-02 |
Teva Pharmaceutical Industries, Ltd. |
Stable laquinimod preparations
|
|
ES2329327B1
(es)
|
2008-03-19 |
2010-09-17 |
Proyecto De Biomedicina Cima, S.L. |
Combinaciones sinergicas de 5'-metiltioadenosina.
|
|
AU2009288108B2
(en)
|
2008-09-03 |
2013-10-17 |
Teva Pharmaceutical Industries, Ltd. |
2-oxo-1,2-dihydro-quinoline modulators of immune function
|
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基－雜環化合物
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
NZ597378A
(en)
|
2009-06-19 |
2014-08-29 |
Teva Pharma |
Treatment of multiple sclerosis with laquinimod
|
|
BR112012002124A2
(pt)
|
2009-07-30 |
2015-09-15 |
Teva Pharma |
tratamento da doença de crohn com laquinimode.
|
|
WO2011019375A1
(en)
|
2009-08-10 |
2011-02-17 |
Teva Pharmaceutical Industries Ltd. |
Treatment of bdnf-related disorders using laquinimod
|
|
DE102010026879A1
(de)
*
|
2010-02-11 |
2011-08-11 |
AMW GmbH, 83627 |
Transdermales System mit Immunmodulator
|
|
EA201290860A1
(ru)
|
2010-03-03 |
2013-04-30 |
Тева Фармасьютикал Индастриз Лтд. |
Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
|
|
KR20130006640A
(ko)
|
2010-03-03 |
2013-01-17 |
테바 파마슈티컬 인더스트리즈 리미티드 |
라퀴니모드를 이용한 루푸스 신장염의 치료
|
|
US20110217295A1
(en)
|
2010-03-03 |
2011-09-08 |
Asi Haviv |
Treatment of lupus arthritis using laquinimod
|
|
AU2011274496B2
(en)
|
2010-07-09 |
2016-03-10 |
Teva Pharmaceutical Industries Ltd. |
Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
|
|
JP5934202B2
(ja)
|
2010-07-09 |
2016-06-15 |
テバ ファーマシューティカル インダストリーズ リミティド |
５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用
|
|
PE20140872A1
(es)
|
2010-12-07 |
2014-08-09 |
Teva Pharma |
Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple
|
|
WO2012131539A1
(en)
|
2011-03-31 |
2012-10-04 |
Pfizer Inc. |
Novel bicyclic pyridinones
|
|
SG10201606191PA
(en)
|
2011-07-28 |
2016-09-29 |
Teva Pharma |
Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
|
|
HK1198278A1
(en)
|
2011-07-28 |
2015-03-27 |
Teva Pharmaceutical Industries Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
|
|
SG11201401330YA
(en)
|
2011-10-12 |
2014-05-29 |
Teva Pharma |
Treatment of multiple sclerosis with combination of laquinimod and fingolimod
|
|
MX2014009889A
(es)
|
2012-02-16 |
2014-11-13 |
Teva Pharma |
N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
|
|
US20130259856A1
(en)
|
2012-03-27 |
2013-10-03 |
Teva Pharmaceutical Industries, Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
|
|
TW201804997A
(zh)
|
2012-05-02 |
2018-02-16 |
以色列商泰瓦藥品工業有限公司 |
高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
|
|
TW201350467A
(zh)
|
2012-05-08 |
2013-12-16 |
Teva Pharma |
Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
|
|
TW201400117A
(zh)
|
2012-06-05 |
2014-01-01 |
Teva Pharma |
使用拉喹莫德治療眼發炎疾病
|
|
WO2014004733A1
(en)
|
2012-06-26 |
2014-01-03 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
AR091706A1
(es)
|
2012-07-11 |
2015-02-25 |
Teva Pharma |
Formulaciones de laquinimod sin agentes alcalinizantes
|
|
UY34896A
(es)
|
2012-07-12 |
2014-02-28 |
Teva Pharma |
Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
|
|
TW201410243A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
TW201410244A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
MX2015004564A
(es)
|
2012-10-12 |
2015-07-21 |
Teva Pharma |
Laquinimod para producir el daño talamico en la esclerosis multiple.
|
|
EA201590788A1
(ru)
|
2012-11-07 |
2015-12-30 |
Тева Фармасьютикал Индастриз Лтд. |
Аминные соли лахинимода
|
|
KR20150119227A
(ko)
|
2013-02-15 |
2015-10-23 |
테바 파마슈티컬 인더스트리즈 리미티드 |
라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
|
|
WO2014152009A1
(en)
|
2013-03-14 |
2014-09-25 |
Teva Pharmaceutical Industries Ltd. |
Transdermal formulations of laquinimod
|
|
JP2016514162A
(ja)
|
2013-03-14 |
2016-05-19 |
テバ ファーマシューティカル インダストリーズ リミティド |
ラキニモドナトリウムの結晶およびその製造のための改善された方法
|
|
EP3094330A4
(en)
*
|
2014-01-17 |
2017-09-27 |
Teva Pharmaceutical Industries Ltd |
Treatment of crohn's disease using low doses of laquinimod
|